The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib/II trial of lenvatinib (LEN) plus pembrolizumab (Pembro) in patients (Pts) with endometrial carcinoma.
 
Vicky Makker
No Relationships to Disclose
 
Drew W. Rasco
Employment - START
Consulting or Advisory Role - TaiRx, Inc.
Research Funding - Aeglea Biotherapeutics (Inst); Asana Biosciences (Inst); Bayer (Inst); Celgene (Inst); Eisai (Inst); Five Prime Therapeutics (Inst); Millennium (Inst); Pharmacyclics (Inst); Rexahn Pharmaceuticals (Inst); Santa Maria Biotherapeutics (Inst)
 
Corina E Dutcus
Employment - Eisai
Leadership - Eisai
Research Funding - Eisai
 
Daniel E. Stepan
Employment - Eisai
 
Di Li
Employment - Eisai
 
Emmett V. Schmidt
Employment - Merck
Stock and Other Ownership Interests - Merck; Merck (I)
 
Robert Charles Shumaker
Employment - Eisai
 
Matthew H. Taylor
Honoraria - Blueprint Medicines; Bristol-Myers Squibb; Eisai; Trillium Therapeutics
Consulting or Advisory Role - Blueprint Medicines; Bristol-Myers Squibb; Eisai; Trillium Therapeutics
Speakers' Bureau - Eisai